In this trial of 365 patients with polycythemia vera, they were randomized to Hct goals of <45% or 45-50%; after a median of 31 months, the primary end point (time to CV death or major thrombotic event) occurred in 3% of the lower Hct group and 10% of the higher Hct group. The study now defines Hct targets (<45%) for patients with polycythemia vera (abstract).
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.